RNF4通过调控eIF2α促进黑色素瘤发生与治疗耐药
黑色素瘤存在蛋白稳态失衡和靶向治疗快速耐药,但连接机制不明。本研究发现泛素连接酶RNF4通过稳定关键致癌蛋白促进肿瘤发生并介导靶向治疗耐药,且该作用依赖翻译起始因子eIF2α。RNF4结合并泛素化稳定磷酸化eIF2α,形成正反馈环路,促进致癌翻译与蛋白稳定。
要点
- RNF4通过稳定致癌蛋白促进黑色素瘤发生并导致靶向治疗耐药
- RNF4与p-eIF2α形成正反馈环路,连接致癌翻译与蛋白稳定
- RNF4和p-eIF2α高表达与患者不良预后及MAPK抑制剂耐药相关
核心结论
- RNF4通过稳定致癌蛋白促进黑色素瘤发生并介导靶向治疗耐药,该作用依赖eIF2α。
- RNF4与p-eIF2α形成正反馈环路,连接致癌翻译与泛素依赖性蛋白稳定。
研究设计与样本
- 研究使用黑色素瘤细胞、异种移植小鼠模型和患者样本。
主要发现
- RNF4蛋白和mRNA水平与患者不良预后及MAPK抑制剂耐药相关。
- RNF4结合、泛素化并稳定磷酸化eIF2α(p-eIF2α),但不影响ATF4或CHOP。
- 高RNF4患者来源黑色素瘤中p-eIF2α水平显著升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Among the hallmarks of melanoma are impaired proteostasis and rapid development of resistance to targeted therapy that represent a major clinical challenge. However, the molecular machinery that links these processes is unknown. Here we describe that by stabilizing key melanoma oncoproteins, the ubiquitin ligase RNF4 promotes tumorigenesis and confers resistance to targeted therapy in melanoma cells, xenograft mouse models, and patient samples. In patients, RNF4 protein and mRNA levels correlate with poor prognosis and with resistance to MAPK inhibitors. Remarkably, RNF4 tumorigenic properties, including therapy resistance, require the translation initiation factor initiation elongation factor alpha (eIF2α). RNF4 binds, ubiquitinates, and stabilizes the phosphorylated eIF2α (p-eIF2α) but not activating transcription factor 4 or C/EBP homologous protein that mediates the eIF2α-dependent integrated stress response. In accordance, p-eIF2α levels were significantly elevated in high-RNF4 patient-derived melanomas. Thus, RNF4 and p-eIF2α establish a positive feed-forward loop connecting oncogenic translation and ubiquitin-dependent protein stabilization in melanoma.
引用
- Avitan-Hersh E, Feng Y, Oknin Vaisman A, et al. Regulation of eIF2α by RNF4 Promotes Melanoma Tumorigenesis and Therapy Resistance. J Invest Dermatol. 2020. PMID: 32360601. doi:10.1016/j.jid.2020.04.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。